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Abstract
Background: Microbubbles (MBs) can serve as an ultrasound contrast agent, and has the potential for magnetic resonance
imaging (MRI). Due to the relatively low effect of MBs on MRI, it is necessary to develop new MBs that are more suitable for
MRI. In this study, we evaluate the properties of SonoVueH and custom-made Fe3O4-nanoparticle-embedded microbubbles
(Fe3O4-MBs) in terms of contrast agents for ultrsonography (US) and MRI.
Methodology/Principal Findings: A total of 20 HepG2 subcutaneous-tumor-bearing nude mice were randomly assigned to
2 groups (i.e., n=10 mice each group), one for US test and the other for MRI test. Within each group, two tests were
performed for each mouse. The contrast agent for the first test is SonoVueH, and the second is Fe3O4-MBs. US was
performed using a Technos
MPX US system (Esaote, Italy) with a contrast-tuned imaging (CnTI
TM) mode. MRI was performed
using a 7.0T Micro-MRI (PharmaScan, Bruker Biospin GmbH, Germany) with an EPI-T2* sequence. The data of signal-to-noise
ratio (SNR) from the region-of-interest of each US and MR image was calculated by ImageJ (National Institute of Health,
USA). In group 1, enhancement of SonoVueH was significantly higher than Fe3O4-MBs on US (P,0.001). In group 2, negative
enhancement of Fe3O4-MBs was significantly higher than SonoVueH on MRI (P,0.001). The time to peak showed no
significant differences between US and MRI, both of which used the same MBs (P.0.05). The SNR analysis of the
enhancement process reveals a strong negative correlation in both cases (i.e., SonoVueH r=20.733, Fe3O4-MBs r=20.903,
with P,0.05).
Conclusions: It might be important to change the Fe3O4-MBs’ shell structure and/or the imagining strategy of US to
improve the imaging quality of Fe3O4-MBs on US. As an intriguing prospect that can be detected by US and MRI, MBs are
worthy of further study.
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Introduction
Angiogenesis is a determinant of tumor growth, invasion, and
metastasis [1]. To detect new tumor microvessels, modern medical
imaging modalities are widely used. As non-invasive imaging tools,
ultrasonography (US) and magnetic resonance imaging (MRI) are
becoming very popular.
With few exceptions, ultrasound contrast agents (UCAs) are
microbubbles (MBs), which are often 1–7 mm in diameter and are
used primarily as blood-pool markers [2]. Since the first
description of enhanced reflections of ultrasound in 1969 [3],
UCAs have developed rapidly and the existing MBs usually have
an inert gas core (sulfur hexafluoride or perfluorocarbon gases)
and a stable shell (denatured albumin, surfactants, or phospholip-
ids). Typical MRI contrast agents include gadolinium chelate,
manganese chelate, and iron compounds. However, in 1991,
Moseley indicated that gas-filled MBs could also be used as a
unique MR contrast agent [4]. Recent theoretical and phantom
studies had further demonstrated this [5–9]. The principle behind
their use in MRI was the gas-liquid interface or the pressure-
induced microbubble size changing, which induced large local
magnetic susceptibility differences.
The current research about MBs and MRI mainly falls into two
categories: (1) using MBs as an MR contract agent based on the
magnetic susceptibility of MBs [10–11], and (2) using MBs as a
medium in MRI based on the biological effects produced by MBs’
cavitation and sonoporation characteristics [12–14]. The first
category of research has received little attention in the literature,
mainly due to the relatively low effect of MBs on MRI. On the
other hand, some researchers found that the potential application
of MBs as a unique intravascular susceptibility contrast agent for
MRI has not been fully studied. Along this line, references [4,10]
have focused on the feasibility study in vivo of MRI with existing
MBs, and references [11,15–19] mainly focused on developing
new MBs that are more suitable for MRI.
In the present study, we are interested in determining the ability
of microbubbles as contrast agents for ultrasonography and
magnetic resonance imaging.
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In vitro US experiments
The signal strength was 92.0867.45, 56.5364.86 for Sono-
VueH and Fe3O4-MBs, respectively. There was a significant
difference (P,0.001). When the imaging strategy changed from
contrast-tuned imaging (CnTI
TM) to the Flash mode, the
SonoVueH microbubbles broke and the enhanced signal generated
by the microbubbles changed to anecho (the signal strength was
8.6263.45, P,0.001, Fig. 1A). However, under the same imaging
strategy change, the signal of Fe3O4-MBs tube had little change as
few microbubbles broke in this case (the signal strength was
50.5466.37, P.0.05, Fig. 1B).
In vitro MRI experiments
Figure 2A includes MR images of different concentration in
SonoVueH and Fe3O4-MBs suspension phantoms. The signal
strength from Fe3O4-MBs was lower than SonoVueH. Figure 2B
shows the dependency of the SNR on different SonoVueH volume
fractions. Figure 2C shows the dependency of the SNR on
different Fe3O4 -MBs volume fractions. An approximately linear
relationship was observed independently (r=20.982 for Sono-
VueH,r=20.929 for Fe3O4-MBs, with P,0.05).
In vivo US imaging
Generally, about 21 days after subcutaneous injection of tumor
cells, the tumor maximum diameter was close to 0.7760.08 cm.
MB contrast enhancement was observed in all 10 mice by US and
all 10 by MRI.
Figure 3 illustrates the images typically observed by US with
SonoVueH and Fe3O4-MBs. Figure 3A shows the gray-scale image
of the tumor. Under CnTI
TM mode just before the MBs injection,
signals from stationary tissues were suppressed and only high
amplitude signals were visualized (Fig. 3B). After the MB
suspension injection, the signal of the tumor enhanced.
Figures 3C and 3D demonstrate the maximum contrast after
injection SonoVueH and Fe3O4-MBs, respectively.
Moreover, Figure 4 illustrates the time-course signal changes
induced by SonoVueH (Figure 4A) and Fe3O4-MBs (Figure 4B)
injection from the same region-of-interest (ROI) and the same
tumor. The average value of enhanced signal observed was
26.14610.95 and 8.5265.83 for SonoVueH and Fe3O4-MBs
during the entire imaging process, respectively, and there was a
significant difference (P,0.001).
In vivo MR imaging
Typical time courses of EPI-T2* images show the similar change
trends as US after MBs administration. Figure 5 illustrates the
mouse tumor images typically observed during SonoVueH and
Fe3O4-MBs injection. Figure 5A shows the anatomy of superficial
tumor. Figure 5B illustrates pre-injection EPI-T2* images. The
post-injection images of SonoVueH and Fe3O4-MBs correspond to
the lowest SNR point in Figures 5C and 5D.
Moreover, Figure 6 illustrates the SNR time-course signal
changes induced by SonoVueH (Figure 6A) and Fe3O4-MBs
(Figure 6B) injection from the same ROI and the same tumor. The
average signal strength was 51.5765.01 and 43.8068.38 for
SonoVueH and Fe3O4-MBs respectively, and there was a
significant difference (P,0.001).
Correlation between the US and MRI
Time-to-peak values were 33.6061.58 s and 34.2061.55 s in
SonoVueH for US and MRI, respectively, and there was no
significant difference (P=0.402). For Fe3O4-MBs, the correspond-
ing values are 26.5061.27 s and 23.8061.69 s for US and MRI,
respectively, and there was no significant difference either
(P=0.404).
Figure 7A denotes the negative correlation of the tumor signal
strength change between US and MRI when both using
SonoVueH. The corresponding correlation is r=20.733 with
p,0.05. Figure 7B shows a similar negative correlation when we
use Fe3O4-MBs in US and MRI instead. The corresponding
correlation in this case is r=20.903 with p,0.05. The above
SNR analyses revealed a strong and significant relationship
between the two modalities when using the same microbubble
contrast agent.
Discussion
Despite the enhancement in different ways, the two typical SNR
time courses showed the similar trend. The tumors were enhanced
rapidly first and washed out gradually. The time of dynamic
enhancement was only a few minutes after injection because of the
limited lifetime of MBs in vivo.
In group 1, Fe3O4-MBs had a lower effect on US than
SonoVueH. The reasons are mainly (1) the Fe3O4-MBs is a
relatively new material and has a hard shell, their acoustic
properties (e.g., acoustic impedance) are somewhat different from
phospholipid-stabilized MBs under the same acoustic energy, so
the intensity of second harmonic is relatively weak. (2) Most of the
Figure 1. In vitro US experiments. Images of SonoVueH and Fe3O4-MBs under the mode of CnTI
TM and Flash: (A) In the first half of the tube, in
CnTIH mode, SonoVueH showed high echo; in the second half, in Flash mode, the SonoVueH microbubbles broke and the enhanced signal generated
by the microbubbles changed to anecho (white arrow). (B) Under the same imaging strategy change, the signal of Fe3O4-MBs tube had little change
(white arrow).
doi:10.1371/journal.pone.0034644.g001
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the properties of SonoVueH. Without changing the imaging
strategies, it is difficult to achieve good imaging properties with the
new Fe3O4-shelled microbubbles. We have conducted many tests
to improve the imaging quality on the existing medical devices.
However, methods such as using higher frequencies or Doppler
based destructive imaging cannot achieve the desirable effects yet.
We are working with several Chinese equipment manufactures on
improving the imaging qualities, hopefully obtaining some positive
results soon.
In group 2, however, SonoVueH had a lower effect on MRI
than Fe3O4-MBs, and the effect of SonoVueH had reached its limit
according to the approaches described for improving microbub-
bles for MRI, which included increasing the radius and volume
fraction of MBs, using inert gas core, et al [8,10]. First, as the size
SonoVueH ranges from 0.1 mm to 1.1 mm (with a mean diameter is
2.5 micrometer according to manual), thus the diameter should
not be increased significantly or they will not pass through the
pulmonary circulation. Second, the microbubble concentration
used in our study was 0.1 mL of the ,3.5% volume fraction,
which was far more than the common maximum clinical dosage
(e.g., 0.08 mL/kg of the 0.8% volume fraction according to the
product description) [10]. Third, the gas core is already sulfur
hexafluoride. Since an inert gas has a high molecular weight and
low solubility, it can cause the largest effect on transverse
relaxation.
Comparing with SonoVueH, the most important change in the
custom-made MBs was that some Fe3O4 nanoparticles had been
embedded into a double-polymer shell. Fe3O4 are T2 agents as
MBs, and they can enhance the magnetic sensitivity for the MBs
[11,18]. As the thick shell [20], the susceptibility of US is reduced.
Changing the characteristics of the shell and/or the imagining
strategy on US may be the most important factor in improving the
effectiveness for US. After all, a combination of multiple modalities
can offer synergistic advantages over any modality alone [21].
In a closely related paper [22], the authors reported an early
contrast study of tumor perfusion using US and MRI. They used
MBs as the contrast agent for US and gadopentetate dimeglumine
as the contract agent for MRI. And found that using MBs in US
can achieve the same effect as using gadopentetate dimeglumine in
MR imaging. As an intriguing prospect that can be detected by US
and MRI, MBs are worthy of further study.
Materials and Methods
In vitro US experiments
A microbubble phantom study was performed (L.L., Q.W.,
H.B.L.) to measure SNR of SonoVueH and Fe3O4-MBs
suspension using a Technos
MPX US system (Esaote, Italy) with a
linear-array transducer (LA532E, 7.5 MHz for fundamental gray-
scale imaging and 2.5 MHz for CnTI
TM). Fe3O4-MBs was kindly
provided by Dr. Fang Yang [18], which had double polymer shells
with 86.47 mg/mL Fe3O4 nanoparticles in it and N2 gas core and
Figure 2. In vitro MRI experiments. The in vitro MR images of different volume fraction of SonoVueH and Fe3O4-MBs: (A). 1: sodium chloride
solution (0.9% w/v), 2–4: SonoVueH with different volume fraction (1.75%, 3.5%, 7.0%). 5–7: Fe3O4-MBs with different volume fraction (1.75%, 3.5%,
7.0%). (B) an approximately linear relationship was observed in SonoVueH (r=20.982, P,0.05) between SNR and microbubble volume fraction. (C) an
approximately linear relationship was observed in Fe3O4-MBs (r=20.929, P,0.05) between SNR and microbubble volume fraction.
doi:10.1371/journal.pone.0034644.g002
Figure 3. Representative US findings with SonoVueH and Fe3O4-MBs. Images from the same mouse: (A) gray-scale image of the tumor with
a size 0.79 mm60.34 mm, (B) under CnTI
TM mode just before microbubble injection, signals from tumor was suppressed (white arrow), (C) maximum
contrast enhancement US tumor image after SonoVueH injection (white arrow), and (D) maximum contrast enhancement US tumor image after
Fe3O4-MBs injection (white arrow).
doi:10.1371/journal.pone.0034644.g003
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and placed in silica gel tubes of 1.0 cm in diameter. They were
diluted to 3.5% volume fractions with sodium chloride solution
(0.9% w/v) and put in a de-gassed water tank. Two experiments
were conducted, one under CnTI
TM imaging and the other under
Flash imaging. The CnTI
TM parameters were as follows: the gain
was 105, the depth was 31 mm, and the mechanical index (MI)
was 0.089, while in the Flash mode the MI was 0.5.
In vitro MRI experiments
A microbubble phantom study was performed (L.L.,S.W.) to
measure SNR of Fe3O4-MBs and SonoVueH suspension using a
7.0T Micro-MRI (PhamaScan, Bruker, Germany). The samples
were mixed and placed in Eppendorf tubes of 1.0 cm in diameter.
They were diluted to 7.0%, 3.5%, and 1.75% volume fractions
with sodium chloride solution (0.9% w/v) respectively. Every
phantom was scanned three times. The imaging parameters for
T2-weighted fast spin echo were set as repetition time
(TR)=3000 ms, echo time (TE)=60 ms, number of excitations
(NEX)=1.
Microbubble preparation for in vivo experiments
The first contrast agent used was SonoVueH. The second
contrast agent used was Fe3O4-MBs. For each group, the dosages
are all 0.1 mL of microbubble suspension with a volume fraction
of about 3.5%. Before each injection, re-suspension must be
performed.
Cell culture and animal model
All animal procedures were performed in accordance with the
approval and guidelines of the Institutional Animal Care and Use
Committee (IACUC) of the Medical School of Southeast
University (approval ID: SYXK-2007.2121).
Cells from the human hepatocellular liver carcinoma cell line
HepG2 (Keygen Biotech. Co., Ltd, Nanjing, China) were grown in
RPMI 1640 with 10% fetal bovine serum (FBS) in a 5% CO2
humidified atmosphere at 37uC. Tumors were established in 20
healthy BALB/c-nu mice (5–6 weeks old, 20–25 g in weight) in
random order by subcutaneous injection of a suspension of 2610
7
HepG2 cells in 0.2 mL of phosphate-buffered saline (PBS) in the
right leg. Tumors were allowed to grow until the greatest diameter
of the tumors was close to 0.8 cm.
Animal preparation
A total of 20 HepG2 subcutaneous-tumor-bearing nude mice
were randomly assigned to 2 groups (i.e., n=10 mice each group),
one for the US test, and the other for the MRI test. Within each
group, two tests were performed for each mouse. The contrast
agent for the first test is SonoVueH, and the second is Fe3O4-MBs.
For US, all mice were kept anesthetized with intraperitoneal
injection of 10% chloral hydrate (3 mL/kg). For MRI, mice were
Figure 4. SNR time courses of the same mouse tumor in US by using SonoVueH and Fe3O4-MBs. Figure A shows the SNR time course in
ROI during SonoVueH injection and Figure B shows the SNR time course when using Fe3O4-MBs injection.
doi:10.1371/journal.pone.0034644.g004
Figure 5. Representative MRI findings with SonoVueH and Fe3O4-MBs. Images from the same mouse during microbubble injection: (A)
anatomical image showing the superficial tumor (white arrow), (B) pre-injection EPI-T2* MRI tumor image (white arrow), (C) maximum contrast
enhancement of the tumor after SonoVueH injection (white arrow), and (D) maximum contrast enhancement of the tumor after Fe3O4-MBs injection
(white arrow).
doi:10.1371/journal.pone.0034644.g005
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monitoring. A 30-G needle was inserted into a tail vein by
intravenous injection of the bubbles with a 40-cm long PE-10 tube.
The dose of MBs was 0.1 mL and 0.2 mL of saline flush was
administered immediately after MBs injected.
In vivo US experiments
Before each examination, each mouse was fixed in a left lateral
position on a warm pad to maintain the body temperature. As the
tumor was just under the skin, about a 2-mm deep US gel was
placed between the transducer surface and the skin to ensure the
tumor was imaged clearly by US.
US imaging was performed (L.L., Q.W., H.B.L.) using a
Technos
MPX US system under CnTI
TM mode. The CnTI
TM
parameters were maintained during all examinations: the gain was
105, the depth was 31 mm, the MI was 0.089 and the scan time
was 1 s. When the optical imaging plane was obtained (the tumor’s
largest transverse cross section), the transducer was maintained
with a mechanical fixer. MB suspension was injected about 5 min
after the CnTI
TM was triggered and images were recorded
digitally on a hard disk for 15 min for off-line analysis. The data of
SNR from the ROI of each US image was calculated by ImageJ (a
software by National Institute of Health, USA). The time-course of
the corresponding parameter SNR was measured.
For each mouse, SonoVueH check was done first. After the
sufficient clearance of the MBs, Fe3O4-MBs suspension was
injected.
Figure 6. SNR time courses of MRI from SonoVueH and Fe3O4-MBs. Figure A shows the SNR time course in ROI during SonoVueH injection
and Figure B shows the SNR time course when using Fe3O4-MBs.
doi:10.1371/journal.pone.0034644.g006
Figure 7. Correlation between the US and MRI. Figure A shows the signal strength correlation between US and MRI in 600 seconds of
enhancement when using SonoVueH (r=20.733, P,0.05). Figure B shows the signal strength correlation between US and MRI in 600 seconds of
enhancement when using Fe3O4-MBs (r=20.903, P,0.05).
doi:10.1371/journal.pone.0034644.g007
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MRI was performed (L.L., S.W.) using a 7.0T Micro-MRI with
a 38-mm volume coil. Each mouse was placed in the prone
position and dynamic susceptibility imaging was performed using
an EPI-T2* sequence with the respiratory gating control. To
obtain better images and shorten the scan time as much as
possible, parameters were adjusted as follows: TR=1000 ms;
TE=30 ms; field of view (FOV)=464 cm; FA=90u; NEX=1;
scan time=1 s; slice thickness=1 mm. Anatomical images were
acquired under another protocol using the following parameters:
TR=2500 ms; TE=33 ms; FOV=464 cm; FA=180u;
NEX=1; scan time=1 min20 s; slice thickness=1 mm. MB
suspension was injected about 5 min after the start of the dynamic
imaging and the total scanning time was 15 min. All images were
recorded digitally on a hard disk for off-line analysis. ROI analyses
were conducted as described for US and the SNR time course was
also measured.
For each mouse, SonoVueH check was done first then was the
Fe3O4-MBs.
Statistical analyses
Statistical evaluation was performed using SPSS software
(ver.13.0; SPSS Inc., Chicago, IL, USA). The numerical results
were expressed as means6SD. Results were analyzed statistically
using the paired-samples t test (for comparing the average signal
strengths of using different MBs in US or MRI) and independent-
samples t test (for comparing the time-to-peak average signal
strengths of using the same MBs in US and MRI) for effectiveness
of different MBs and modalities. Pearson correlation coefficient of
SNR is for US and MRI.
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